Aurinia Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Aurinia Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Aurinia Pharmaceuticals Inc Strategy Report
- Understand Aurinia Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Aurinia Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| WO2022153250A1 | Application | PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITY | A61K38/13; A61P37/06; A61P39/00; C07K7/64; G01N33/48 | July 21, 2022 |
| US20220226428A1 | Application | PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS | A61K31/343; A61K38/13; A61P13/12; A61P37/00 | July 21, 2022 |
| CA3014633C | Grant | OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR MTOR INHIBITORS | A61K31/355; A61K31/436; A61K31/56; A61K38/13; A61K47/32; A61K9/0048; A61K9/1075; A61P27/02; A61P27/04; A61P27/14; A61P29/00; A61P31/04; A61P37/06; A61P9/10 | May 17, 2022 |
| WO2021224890A1 | Application | METHODS OF TREATING OR PREVENTING CORONAVIRUS INFECTION | A61K31/5377; A61K38/13; A61K45/06; A61K47/26; A61K9/0019; A61K9/0078; A61K9/08; A61P31/12; A61P31/14 | November 11, 2021 |
| US20210338769A1 | Application | OPHTHALMIC COMPOSITIONS | A61K31/355; A61K31/436; A61K31/56; A61K38/13; A61K47/32; A61K9/0048; A61K9/1075; A61P27/02; A61P27/04; A61P27/14; A61P29/00; A61P31/04; A61P37/06; A61P9/10 | November 04, 2021 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer